Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-008 (Nab-docetaxel) in Hormone-refractory Prostate Cancer
NCT00477529Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2007
- Primary completion
- Jun 2011
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of albumin-bound docetaxel in prostate cancer (PCa), sponsored by Celgene Corporation. Primary endpoint: Dose-Limiting Toxicities and Maximum Tolerated Dose at 1 year. Started Apr 2007; status: completed.
02
Drugs
albumin-bound docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00477529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00477529.